AIM ImmunoTech Says Data From Completed Phase 2 Cisplatin-Resistant Advanced Recurrent Ovarian Cancer Clinical Study Utilizing Ampligen Accepted In Late-Breaking Abstract At Annual SITC Meeting

AIM ImmunoTech Inc. Common Stock +6.17% Pre

AIM ImmunoTech Inc. Common Stock

AIM

0.58

0.58

+6.17%

-0.55% Pre
AIM ImmunoTech Says Data From Completed Phase 2 Cisplatin-Resistant Advanced Recurrent Ovarian Cancer Clinical Study Utilizing Ampligen Accepted In Late-Breaking Abstract At Annual SITC Meeting
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.